Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
83.29
+3.81 (4.79%)
At close: Mar 31, 2026, 4:00 PM EDT
84.00
+0.71 (0.85%)
After-hours: Mar 31, 2026, 7:53 PM EDT
Kymera Therapeutics Employees
Kymera Therapeutics had 238 employees as of December 31, 2025. The number of employees increased by 50 or 26.60% compared to the previous year.
Employees
238
Change
50
Growth
26.60%
Revenue / Employee
$164,752
Profits / Employee
-$1,308,197
Market Cap
6.80B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 238 | 50 | 26.60% |
| Sep 30, 2025 | 225 | 41 | 22.28% |
| Jun 30, 2025 | 218 | 37 | 20.44% |
| Mar 31, 2025 | 208 | 22 | 11.83% |
| Dec 31, 2024 | 188 | 1 | 0.53% |
| Sep 30, 2024 | 184 | -8 | -4.17% |
| Jun 30, 2024 | 181 | 0 | - |
| Mar 31, 2024 | 186 | 12 | 6.90% |
| Dec 31, 2023 | 187 | 20 | 11.98% |
| Sep 30, 2023 | 192 | 23 | 13.61% |
| Jun 30, 2023 | 181 | 21 | 13.13% |
| Mar 31, 2023 | 174 | 31 | 21.68% |
| Dec 31, 2022 | 167 | 26 | 18.44% |
| Sep 30, 2022 | 169 | 33 | 24.26% |
| Jun 30, 2022 | 160 | 48 | 42.86% |
| Mar 31, 2022 | 143 | 51 | 55.43% |
| Dec 31, 2021 | 141 | 66 | 88.00% |
| Sep 30, 2021 | 136 | 72 | 112.50% |
| Jun 30, 2021 | 112 | 57 | 103.64% |
| Mar 31, 2021 | 92 | 37 | 67.27% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ImmunityBio | 691 |
| Halozyme Therapeutics | 423 |
| Rhythm Pharmaceuticals | 414 |
| Krystal Biotech | 295 |
| Apogee Therapeutics | 261 |
| Cogent Biosciences | 258 |
| Arcellx | 209 |
| Protagonist Therapeutics | 132 |
KYMR News
- 3 days ago - Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting - GlobeNewsWire
- 19 days ago - Kymera Therapeutics, Inc. (KYMR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 21 days ago - Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting - GlobeNewsWire
- 4 weeks ago - Kymera Therapeutics: Well-Funded Pipeline Enters A Defining Clinical Phase - Seeking Alpha
- 4 weeks ago - Kymera Therapeutics, Inc. (KYMR) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - GlobeNewsWire
- 2 months ago - Kymera Therapeutics, Inc. (KYMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs - GlobeNewsWire